Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $724.54 million. The enterprise value is $431.73 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 107.74 million shares outstanding. The number of shares has increased by 13.04% in one year.
| Current Share Class | 107.74M |
| Shares Outstanding | 107.74M |
| Shares Change (YoY) | +13.04% |
| Shares Change (QoQ) | +12.88% |
| Owned by Insiders (%) | 2.42% |
| Owned by Institutions (%) | 80.00% |
| Float | 81.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 2.16 |
| PB Ratio | 1.74 |
| P/TBV Ratio | 2.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.19, with a Debt / Equity ratio of 0.06.
| Current Ratio | 9.19 |
| Quick Ratio | 9.01 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -143.20 |
Financial Efficiency
Return on equity (ROE) is -60.45% and return on invested capital (ROIC) is -37.33%.
| Return on Equity (ROE) | -60.45% |
| Return on Assets (ROA) | -34.80% |
| Return on Invested Capital (ROIC) | -37.33% |
| Return on Capital Employed (ROCE) | -62.01% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$862,963 |
| Employee Count | 299 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.24% in the last 52 weeks. The beta is 1.02, so RCKT's price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | -71.24% |
| 50-Day Moving Average | 7.16 |
| 200-Day Moving Average | 13.11 |
| Relative Strength Index (RSI) | 47.60 |
| Average Volume (20 Days) | 3,146,957 |
Short Selling Information
The latest short interest is 12.26 million, so 11.38% of the outstanding shares have been sold short.
| Short Interest | 12.26M |
| Short Previous Month | 13.30M |
| Short % of Shares Out | 11.38% |
| Short % of Float | 14.98% |
| Short Ratio (days to cover) | 3.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -270.22M |
| Pretax Income | -253.26M |
| Net Income | -258.03M |
| EBITDA | -260.11M |
| EBIT | -270.22M |
| Earnings Per Share (EPS) | -$2.61 |
Full Income StatementBalance Sheet
The company has $318.16 million in cash and $25.35 million in debt, giving a net cash position of $292.81 million or $2.72 per share.
| Cash & Cash Equivalents | 318.16M |
| Total Debt | 25.35M |
| Net Cash | 292.81M |
| Net Cash Per Share | $2.72 |
| Equity (Book Value) | 412.14M |
| Book Value Per Share | 3.86 |
| Working Capital | 289.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$208.66 million and capital expenditures -$4.19 million, giving a free cash flow of -$212.85 million.
| Operating Cash Flow | -208.66M |
| Capital Expenditures | -4.19M |
| Free Cash Flow | -212.85M |
| FCF Per Share | -$1.98 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |